FAPI-74 PET/MRI for Dermatomyositis
(FAPI-74 Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Farshad Moradi

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.

Eligibility Criteria

This trial is for individuals with refractory dermatomyositis, a condition where standard treatments haven't worked. Participants must meet certain health criteria to be included, but specific inclusion and exclusion details are not provided in the given information.

Inclusion Criteria

I might have dermatomyositis.

Be willing and able to provide written informed consent for the trial

I am over 18 years old.

Exclusion Criteria

I cannot have an MRI or lie flat for 30 minutes.

I am not pregnant nor planning to become pregnant soon.

Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study

Participant Groups

[18F]-FAPI-74 PET/MRI imaging is being tested in this study. It's a single-center, single-arm trial which means all participants will receive the same intervention without comparison to another group or treatment.

1Treatment groups

Experimental Treatment

Group I: [18F]-FAPI-74 PET/ MRIExperimental Treatment1 Intervention

Participant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.